You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Fluticasone propionate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for fluticasone propionate and what is the scope of patent protection?

Fluticasone propionate is the generic ingredient in twenty branded drugs marketed by Glaxosmithkline, Glaxo Grp Ltd, Fougera Pharms, Cosette, Encube, Nesher Pharms, Padagis Israel, Glenmark Pharms Ltd, Bright, Taro Pharm Inds, Teva Pharm, Haleon Us Holdings, Apotex, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Hikma, Optinose Us Inc, Teva Pharms Usa, and Mylan, and is included in thirty-seven NDAs. There are forty-seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fluticasone propionate has eight hundred and two patent family members in forty countries.

There are twenty-four drug master file entries for fluticasone propionate. Seventy-two suppliers are listed for this compound.

Drug Prices for fluticasone propionate

See drug prices for fluticasone propionate

Drug Sales Revenue Trends for fluticasone propionate

See drug sales revenues for fluticasone propionate

Recent Clinical Trials for fluticasone propionate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eurofarma Laboratorios S.A.Phase 3
Humanis Saglık Anonim SirketiPhase 1
Emory UniversityPhase 3

See all fluticasone propionate clinical trials

Pharmacology for fluticasone propionate
Paragraph IV (Patent) Challenges for FLUTICASONE PROPIONATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FLOVENT HFA Inhalation Aerosol fluticasone propionate 0.22 mg/inh 021433 1 2021-10-29
FLOVENT HFA Inhalation Aerosol fluticasone propionate 0.11 mg/inh 021433 1 2016-12-23
CUTIVATE Lotion fluticasone propionate 0.05% 021152 1 2008-07-28

US Patents and Regulatory Information for fluticasone propionate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-006 Feb 20, 2020 DISCN Yes No 11,357,935*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 DISCN Yes No 10,561,808*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 DISCN Yes No 10,765,820*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-006 Jul 12, 2019 DISCN Yes No 10,022,510*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-004 Feb 20, 2020 DISCN Yes No 10,124,131*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-003 Jan 27, 2017 RX Yes Yes 11,969,544*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-004 Feb 20, 2020 DISCN Yes No 10,765,820*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fluticasone propionate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 6,701,917 ⤷  Subscribe
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-001 May 14, 2004 7,832,351*PED ⤷  Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 100 fluticasone propionate POWDER;INHALATION 020833-002 Sep 29, 2000 7,225,808*PED ⤷  Subscribe
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-001 May 14, 2004 6,510,969*PED ⤷  Subscribe
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-001 May 14, 2004 6,743,413*PED ⤷  Subscribe
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 8,327,844 ⤷  Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 6,378,519*PED ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for fluticasone propionate

Country Patent Number Title Estimated Expiration
Mexico 2017002552 MODULO DE MONITOREO DE CUMPLIMIENTO PARA UN INHALADOR ACCIONADO POR RESPIRACION. (COMPLIANCE MONITORING MODULE FOR A BREATH-ACTUATED INHALER.) ⤷  Subscribe
Poland 206318 ⤷  Subscribe
Spain 2544278 ⤷  Subscribe
Spain 2529229 ⤷  Subscribe
Slovenia 1667627 ⤷  Subscribe
Slovenia 1699434 ⤷  Subscribe
Eurasian Patent Organization 201300235 ИНГАЛЯТОР ДЛЯ ВДЫХАНИЯ ЛЕКАРСТВЕННОГО ВЕЩЕСТВА ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for fluticasone propionate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 2018C/022 Belgium ⤷  Subscribe PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329 SPC/GB08/026 United Kingdom ⤷  Subscribe PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
1519731 132013902182575 Italy ⤷  Subscribe PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
1519731 13C0067 France ⤷  Subscribe PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1305329 08C0014 France ⤷  Subscribe PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1519731 92269 Luxembourg ⤷  Subscribe PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2506844 LUC00077 Luxembourg ⤷  Subscribe PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Fluticasone propionate Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Fluticasone Propionate

Market Overview

Fluticasone propionate, a widely used glucocorticoid, is a key player in the treatment of various respiratory and dermatological conditions. Here’s a detailed look at the market dynamics and financial trajectory of this drug.

Market Size and Growth

The global fluticasone propionate inhalers market is projected to experience significant growth. As of 2023, the market size was valued at approximately USD 5.6 billion and is expected to reach USD 8.1 billion by 2032, growing at a CAGR of about 4.6% during the forecast period[1].

Key Market Segments

The fluticasone propionate market is segmented based on several criteria:

  • By Type: The market is classified into 60 metered sprays, 120 metered sprays, and 150 metered sprays. These different formulations cater to various patient needs and treatment durations[1][4].
  • By Application: The market is segmented into two main application categories: kids and adults. This segmentation helps in tailoring the treatment to the specific age group and their respective health needs[1][4].

Driving Factors

Several factors are driving the growth of the fluticasone propionate market:

  • Increasing Incidence of Respiratory Problems: The rising prevalence of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) is a significant driver. As more people are diagnosed with these conditions, the demand for effective treatments like fluticasone propionate increases[1].
  • Technological Advancements: Advances in medical technology, including the development of more efficient inhaler devices and novel drug delivery systems, are enhancing the efficacy and convenience of fluticasone propionate treatments. For example, the Exhalation Delivery System (EDS) used in products like XHANCE improves the delivery of the medication deep into the nasal passages[3].

Cost-Effectiveness

Fluticasone propionate has been shown to be more cost-effective compared to other inhaled corticosteroids like budesonide. A pharmacoeconomic analysis revealed that treatment with fluticasone propionate was cheaper, with weekly costs of 7.78 Pounds compared to 12.33 Pounds for budesonide. The lower costs are attributed to reduced healthcare contacts and better efficacy in improving symptoms and reducing episodes of respiratory distress[2].

Geographical Insights

The market for fluticasone propionate is spread across various geographical regions:

  • North America: This region is expected to dominate the market due to a large consumer base and high healthcare expenditure. The presence of advanced healthcare infrastructure and increased awareness about respiratory conditions also contribute to the market growth in this region[3][4].
  • Europe, Asia-Pacific, and Other Regions: These regions also show significant growth potential, driven by increasing healthcare spending, rising awareness, and technological advancements[4].

Competitive Landscape

The fluticasone propionate market is competitive, with several key players:

  • GSK, Teva, West-ward Pharmaceuticals, Apotex Corp., Akorn, Wockhardt: These companies are actively involved in the development, manufacturing, and marketing of fluticasone propionate products. Their investments in research and development, as well as their market expansion strategies, play a crucial role in shaping the market[4].

Regulatory and Clinical Use

Fluticasone propionate is widely used in clinical practice for various indications, including asthma, COPD, and dermatological conditions like atopic dermatitis. The drug has been nominated for inclusion on the 503B Bulks List, which could further expand its use in compounded products. Clinical use and nominations highlight its efficacy and safety profile, supporting its continued market growth[5].

Challenges and Restraints

Despite the positive outlook, there are several challenges that the fluticasone propionate market faces:

  • Regulatory Hurdles: Strict regulatory requirements and the need for continuous compliance can impede market growth. Ensuring that products meet FDA standards is crucial but can be time-consuming and costly[3].
  • Economic Factors: Economic downturns, such as those caused by the COVID-19 pandemic, can lead to reduced healthcare spending and delayed medical treatments, affecting market demand[3].

Future Outlook

The future of the fluticasone propionate market looks promising, driven by increasing demand for effective respiratory treatments and advancements in medical technology.

"Advances in medical technology have led to the development of more effective and targeted treatments for respiratory conditions. Novel drug delivery systems, such as nasal sprays and inhalers, offer improved efficacy and convenience for patients."[3]

Key Takeaways

  • The global fluticasone propionate inhalers market is expected to grow at a CAGR of 4.6% from 2023 to 2032.
  • The market is driven by increasing incidence of respiratory problems and technological advancements.
  • Fluticasone propionate is more cost-effective than other inhaled corticosteroids like budesonide.
  • North America is expected to dominate the market due to a large consumer base and high healthcare expenditure.
  • Key players are investing in research and development to expand their product portfolios.

FAQs

What is the expected market size of fluticasone propionate inhalers by 2032?

The fluticasone propionate inhalers market is expected to reach USD 8.1 billion by 2032[1].

What is the CAGR of the fluticasone propionate inhalers market?

The market is expected to exhibit a CAGR of about 4.6% during the forecast period[1].

What are the key segments of the fluticasone propionate market?

The market is segmented based on type (60 metered sprays, 120 metered sprays, 150 metered sprays) and application (kids, adults)[1][4].

Why is fluticasone propionate more cost-effective than budesonide?

Fluticasone propionate is more cost-effective due to lower healthcare contact costs and better efficacy in improving symptoms and reducing episodes of respiratory distress[2].

Which region is expected to dominate the fluticasone propionate market?

North America is expected to dominate the market due to a large consumer base and high healthcare expenditure[3][4].

What are the main drivers of the fluticasone propionate market?

The main drivers include increasing incidence of respiratory problems and technological advancements in medical treatments[1][3].

Sources

  1. Business Research Insights: Fluticasone Propionate Inhalers Market Size, Share & Report, 2032.
  2. PubMed: The cost-effectiveness of inhaled fluticasone propionate.
  3. Business Research Insights: Sinusitis Medicine Market Size [2024 to 2032] | Global Forecast.
  4. Market Research Intellect: Global fluticasone propionate market size and forecast.
  5. University of Maryland, Baltimore: Fluticasone propionate - Summary Report.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.